The predictive value of purified protein derivative results on complications and prognosis in patients with bladder cancer treated with bacillus Calmette-Guerin

被引:31
作者
Bilen, CY [1 ]
Inci, K [1 ]
Erkan, I [1 ]
Özen, H [1 ]
机构
[1] Hacettepe Univ, Sch Med, Dept Urol, Ankara, Turkey
关键词
bladder neoplasms; mycobacterium tuberculosis; administration; intravesical; treatment outcome;
D O I
10.1097/01.ju.0000059681.67567.12
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: We investigate the correlation of purified protein derivative (PPD) results before intravesical bacillus Calmette-Guerin (BCG) instillations with prognosis and complications of BCG. Materials and Methods: A total of 57 men and 4 women with proven intermediate or high risk superficial bladder cancer received 6 courses of intravesical BCG instillations following complete resection of tumors. Skin reactivity to a PPD derivative of Mycobacterium. tuberculosis was tested before starting and 1 week after BCG. The test was considered positive if the induration was 10 mm. or more in diameter after 48 or 72 hours. The patients were grouped according to PPD responses and symptoms. The statistical analyses were performed between PPD positive and negative groups, and also between symptomatic and asymptomatic patients. The groups were compared for relapse rates, time to first recurrence, complication rates and clinical outcome. Results: Most of the patients with systemic side effects were in the PPD positive group but only fever had a statistically significant difference and was more frequent in the positive group (p < 0.05). The recurrence-free intervals after intravesical BCG therapy did not differ significantly between PPD positive and negative groups. However, the trend of longer recurrence-free survival was evident for symptomatic patients (p = 0.056). The numbers of tumor recurrences were 10 (52%) in the PPD negative group and 19 (51%) in the PPD positive group, which was statistically insignificant. Conclusions: Patients with systemic reactions to BCG had the longest disease-free survival. It seems that patients with an augmented reaction to BCG probably have better antitumor activity. Furthermore, although larger groups of patients are mandatory for statistical analysis, this study shows that hypersensitivity reaction against tuberculin could alert physicians of severe complications.
引用
收藏
页码:1702 / 1705
页数:4
相关论文
共 20 条
[1]   A PROSPECTIVE RANDOMIZED TRIAL OF MAINTENANCE VERSUS NONMAINTENANCE INTRAVESICAL BACILLUS CALMETTE-GUERIN THERAPY OF SUPERFICIAL BLADDER-CANCER [J].
BADALAMENT, RA ;
HERR, HW ;
WONG, GY ;
GNECCO, C ;
PINSKY, CM ;
WHITMORE, WF ;
FAIR, WR ;
OETTGEN, HF .
JOURNAL OF CLINICAL ONCOLOGY, 1987, 5 (03) :441-449
[2]   Current use and questions concerning intravesical bladder cancer group for superficial bladder cancer [J].
Dalbagni, G ;
Herr, HW .
UROLOGIC CLINICS OF NORTH AMERICA, 2000, 27 (01) :137-+
[3]   INTRAVESICAL BACILLUS CALMETTE-GUERIN THERAPY FOR SUPERFICIAL BLADDER-CANCER - EFFECT OF BACILLUS CALMETTE-GUERIN VIABILITY ON TREATMENT RESULTS [J].
KELLEY, DR ;
RATLIFF, TL ;
CATALONA, WJ ;
SHAPIRO, A ;
LAGE, JM ;
BAUER, WC ;
HAAFF, EO ;
DRESNER, SM .
JOURNAL OF UROLOGY, 1985, 134 (01) :48-53
[4]  
Lamm D L, 1989, Prog Clin Biol Res, V310, P335
[5]   INCIDENCE AND TREATMENT OF COMPLICATIONS OF BACILLUS-CALMETTE-GUERIN INTRAVESICAL THERAPY IN SUPERFICIAL BLADDER-CANCER [J].
LAMM, DL ;
VANDERMEIJDEN, APM ;
MORALES, A ;
BROSMAN, SA ;
CATALONA, WJ ;
HERR, HW ;
SOLOWAY, MS ;
STEG, A ;
DEBRUYNE, FMJ .
JOURNAL OF UROLOGY, 1992, 147 (03) :596-600
[6]  
LAMM DL, 1992, UROL CLIN N AM, V19, P565
[7]   Intravesical versus intravesical plus intradermal Bacillus Calmette-Guerin: A prospective randomized study in patients with recurrent superficial bladder tumors [J].
Luftenegger, W ;
Ackermann, DK ;
Futterlieb, A ;
Kraft, R ;
Minder, CE ;
Nadelhaft, P ;
Studer, UE .
JOURNAL OF UROLOGY, 1996, 155 (02) :483-487
[8]   INTRACAVITARY BACILLUS CALMETTE-GUERIN IN TREATMENT OF SUPERFICIAL BLADDER TUMORS [J].
MORALES, A ;
EIDINGER, D ;
BRUCE, AW .
JOURNAL OF UROLOGY, 1976, 116 (02) :180-183
[9]  
Mungan NA, 1998, BRIT J UROL, V82, P213
[10]  
Nathanson L, 1974, Semin Oncol, V1, P337